NEW YORK, May 14, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021. Q1 2021 Financial Highlights (in USD) Total assets as of March 31, 2021 were $201 million, including $160 million in cash Net Cash…

Source

Previous articleEntheon Biomedical Corp. Provides Corporate Update
Next articlePsychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A